Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

ONTY $3.01 0.5000 +19.92%
CBMG $35.64 4.5100 +14.49%
BLRX $2.02 0.1700 +9.19%
XBIT $20.59 1.5400 +8.08%
INO $8.83 0.5700 +6.90%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

CALA $11.00 -1.0200 -8.49%
TKAI $10.95 -0.9100 -7.67%
CLSN $2.63 -0.1701 -6.08%
CVM $0.75 -0.0400 -5.06%
BDSI $8.10 -0.3900 -4.59%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | Next > | Last >>

Acacia Pharma Announces Positive Results From Phase 2 Study With APD403 in Chemotherapy Induced Nausea & Vomiting (CINV)

(Yahoo! Finance) May 6, 2015 - Acacia Pharma Ltd, a specialty pharmaceutical company developing supportive care products for post-surgical and cancer patients in the US and international markets, announces positive results from its Phase 2 study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV).
read article 

Investigational Medicine Venetoclax Receives Breakthrough Therapy Designation in Relapsed or Refractory Chronic Lymphocytic Leukemia in Previously Treated Patients with the 17p Deletion Genetic Mutation

(MarketWatch) May 6, 2015 - AbbVie plans to submit regulatory applications for venetoclax to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) before the end of 2015-- Venetoclax is currently in development for the treatment of relapsed or refractory chronic lymphocytic leukemia, including patients with 17p deletion.
read article 

Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Gastric Cancer

(TheStreet) May 6, 2015 - Oncolytics Biotech Inc. today announced that the FDA has granted an Orphan Drug Designation (ODD) for its lead product candidate, REOLYSIN®, for the treatment of gastric cancer.
read article 

EMD Serono Initiates Co-Promotion of XALKORI® (crizotinib) with Pfizer in the United States

(EMD Serono) May 6, 2015 - EMD Serono, the U.S. biopharmaceutical business of Merck KGaA, Darmstadt, Germany, today announced it has begun co-promoting Pfizer's anaplastic lymphoma kinase (ALK) inhibitor XALKORI® (crizotinib) as part of its global strategic alliance with Pfizer.
read corporate press release 

Gilead Sciences Acquires EpiTherapeutics

(Yahoo! Finance) May 6, 2015 - Deal adds small molecule inhibitors against targets involved in epigenetic regulation.
read article 

Juno Therapeutics and Fate Therapeutics Announce Strategic Research Collaboration to Improve the Therapeutic Profile of Engineered T Cell Immunotherapies

(Fate Therapeutics) May 6, 2015 - Juno Therapeutics, Inc. and Fate Therapeutics, Inc. announced today that they have executed a strategic research collaboration and license agreement to identify and utilize small molecules to modulate Juno's genetically-engineered T cell product candidates to improve their therapeutic potential for cancer patients.
read corporate press release 

Lymphoma Pattern Reassuring With Anti-TNF in RA

(Medpage Today/The Gupta Guide) May 5, 2015 - No change in the pattern of lymphomas was seen among patients with rheumatoid arthritis (RA) treated with biologic therapies compared with those not receiving biologics, a large collaborative European analysis showed.
read article (free registration required) 

Conquer Cancer Foundation Recognizes International Oncologists with LIFe and IDEA Awards

(Conquer Cancer Foundation/ASCO) May 5, 2015 - The Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO) announced today the recipients of the 2015 Long-Term International Fellowship (LIFe) and International Development and Education Awards (IDEA).
read press release 

Polish Doctors Perform Rare Throat-area Transplant

( Press) May 5, 2015 - Polish surgeons said Monday they have successfully performed a rare and extensive transplant of the throat area.
read article 

Jury Out on e-Cigs for Smoking Cessation

(Medscape Medical News) May 4, 2015 - There is still insufficient evidence to weigh the balance of benefits and harms of electronic cigarettes for smoking cessation, experts say.
read article (free registration required) 

Nonradiologists Get Most of Medicare Imaging Payments

( May 4, 2015 - More than 50% of Medicare payments for diagnostic imaging services in the U.S. are made to nonradiologists, according to a study published in the May issue of the American Journal of Roentgenology. In fact, Medicare payments to nonradiologists for diagnostic imaging exceed those to radiologists in almost 60% of states.
read article (free registration required) 

Cancer Targeted Technology Receives $2 Million Small Business Innovation (SBIR) Grant to Advance its PET Imaging Diagnostic to Clinical Trials in Prostate Cancer

(MarketWatch) May 4, 2015 - Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on cancer diagnostics and therapeutics, today announced that the NIH awarded a 2-year, $2M SBIR grant to CTT to develop a new agent that will help diagnose and monitor metastatic prostate cancer.
read article 

New Company to Develop Vaccines, Discovered by City of Hope Researchers, to Protect Against CMV Infections in Cancer Patients

( May 4, 2015 - City of Hope and Fortress Biotech have reached an agreement to form a new subsidiary company, DiaVax Biosciences, that will develop two novel vaccines against cytomegalovirus infection, a life-threatening illness in people with weakened or underdeveloped immune systems, such as cancer patients and developing fetuses.
read article 

ArQule and Beryllium Announce Collaborative Research and Development Agreement

(Yahoo! Finance) May 5, 2015 - ArQule and Beryllium announce collaborative research and development agreement; parties to focus on immuno-oncology targets; collaboration provides for target screening through clinical development and commercialization of priority compounds; agreement leverages applications of Beryllium platforms to validate drug targets and new therapies.
read article 

12 Cancer Drugs May Come Under Price Control

(The Indian Express) May 5, 2015 - In a move that could bring relief to thousands of cancer patients, the pharmaceutical pricing authority has recommended the inclusion of 12 drugs used to treat a range of life-threatening conditions, from leukaemia to breast cancer, in the National List of Essential Medicines (NLEM).
read article 

FDA Rejects AcelRx's Request for Meeting on Pain Drug Device

(Reuters) May 4, 2015 - AcelRx Pharmaceuticals Inc said a division of the U.S. Food and Drug Administration had rejected the company's request for a meeting to discuss the need for an additional trial of its pain drug device, Zalviso.
read article 

Bayer to Spend $155m on Isis Blood Thinner

(PharmaTimes [UK]) May 4, 2015 - Bayer has bought itself access to Isis Pharmaceuticals’ experimental anticoagulant ISIS-FXIRx in a deal worth at at least $155 million to the latter.
read article 

New CEO Takes Over at Drugmaker Bristol-Myers Squibb

(New York Times/Associated Press) May 5, 2015 - Drugmaker Bristol-Myers Squibb has a new CEO, this time a physician who trained in Rome.
read article 

China to Stop Setting Most Medicine Prices From June 1

(Reuters) May 5, 2015 - China will remove price caps for most medicines from June 1 and give the market a larger role in setting prices in the world's second largest pharmaceutical market, the country's economic planning agency said on Tuesday.
read article 

UnitedHealth Widens Telehealth Coverage To Millions Of Americans

(Forbes) May 5, 2015 - UnitedHealth Group is offering the widest health insurance coverage yet of doctor visits via telemedicine, offering access to three different medical care provider networks that connect physicians and patients via smart phone, tablet or computer.
read article 

ZIOPHARM Announces Initiation of Phase 1 Study of Ad-RTS-IL-12 Gene Therapy in Patients With Brain Cancer

(TheStreet) May 5, 2015 - ZIOPHARM Oncology, Inc. today announced the initiation of a Phase 1 study of Ad-RTS-hIL-12 + veledimex in patients with recurrent or progressive glioblastoma or Grade III malignant glioma, a form of brain cancer.
read article 

Discovery Could Help Reverse Glucocorticoid Resistance in Some Young Leukemia Patients

(St. Jude) May 4, 2015 - St. Jude Children’s Research Hospital study lays the foundation for more effective treatment of childhood leukemia and a wide range of other disorders using small molecules to reverse glucocorticoid resistance.
read press release 

3D-Printed Trachea among Key Mount Sinai Research Presented at American Association for Thoracic Surgery Meeting

(Icahn School of Medicine/Mount Sinai) May 4, 2015 - Icahn School of Medicine at Mount Sinai researchers presented several landmark studies at the 2015 American Association for Thoracic Surgery (AATS) meeting in Seattle.
read press release 

Profiling Approach to Enable Right Lung Cancer Treatment Match

(University of Manchester [UK]) May 5, 2015 - Manchester researchers have tested a new way to genetically profile lung cancer samples, potentially allowing doctors to more easily identify the most appropriate treatment for patients.
read article 

Trial of New 'Resistance-busting' Skin Cancer Drug Begins as First Patient Receives Treatment

(Institute of Cancer Research [UK]) May 5, 2015 - The first patient has received a new panRAF inhibitor – a new type of drug under development to address the problem of drug resistance in advanced skin cancer and a number of other cancer types.
read press release